MedTrace Logo

Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C

NCT01292161 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2011-02-09

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.

Conditions

  • Hepatitis C

Interventions

DRUG

Silymarin

Tab 210 mg, 630 mg, daily, six months.

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    lead OTHER

Principal Investigators

  • hamid kalantari, A.Professor · Associate Professor,Gasteroentrology department

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01292161 on ClinicalTrials.gov